Sotera Health Q2 net revenue up 8.3% to $277M; adj. EBITDA up 6.9% to $137M

Sotera Health Co

2024-Q2 EPS reported $0.05 revenue$524,770,000

Net income $9M ($0.03 diluted) vs $24M ($0.08) in Q2 2023; decline due to debt refinancing charges.
Adjusted EPS $0.19 vs $0.20; higher interest expense weighed on earnings.
Refinanced debt structure, extending maturities to 2031; reaffirmed 2024 outlook.
First-half 2024 revenue $525M (+10.3%), adj. EBITDA $249M (+9.8%), adj. EPS $0.32.
All three segments (Sterigenics, Nordion, Nelson Labs) reported volume increases in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.